Volume 13 Supplement 2
BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
© Bouchalova et al. 2011
Published: 16 November 2011
Triple-negative breast cancers (TNBCS) are aggressive with poor prognosis. Patients cannot benefit from targeted treatment. Moreover, little is known of which TNBC patients will benefit from nontargeted adjuvant treatment. The objective was to search for predictors of adjuvant chemotherapy in TNBC.
The study included 67 TNBC patients in clinical stages I to III, all but 22 had undergone adjuvant chemotherapy (CMF - 27 patients). FISH using p53, HER1, centromere 7 and 17 probes was performed on tumor tissue. Bcl2 was detected by immunohistochemistry.
HER1 amplification was found in 23.9%, p53 deletion was detected in 29.7% and bcl2 positivity was present in 32.8% tumors. A lower p53/chromosome 17 ratio correlated with higher grading (P = 0.003) and showed a strong trend toward HER1/chromosome 7 ratio (P = 0.053). Patients with a chromosome 17 copy number ≥1.9 had better overall survival than patients with a copy number <1.9 (Kaplan-Meier, P = 0.014). Bcl2-positive patients treated with adjuvant CMF had significantly better disease-free survival than bcl2-negative patients treated with adjuvant CMF (Kaplan-Meier, P < 0.035).
Initial data support the use of a classical CMF regimen in TNBC patients. However, the biomarker of CMF responsiveness is needed for clinical practice. We confirmed the bcl2 positivity as a predictor of CMF sensitivity in TNBC. Thus, validation of this marker in a larger study is needed. Higher chromosome 17 copy number was associated with better outcome, suggesting the importance of its assessment.
Supported by grants IGA NS10286-3, NS9956, MSM6198959216 and Biomedreg CZ.1.05/2.1.00/01.0030.